Evaluation of the COBAS Core II Immunochemistry Analyser
Author Information
Author(s): Jochem K6tting, Gabriele Heinemann, Isolde Salb, Herbert Maier-Lenz
Primary Institution: Tumor Biology Center, Institute for Clinical Pharmacology, Freiburg, Germany
Hypothesis
The COBAS Core II immunoassay analyser will demonstrate good analytical performance and efficiency in an oncology laboratory setting.
Conclusion
The COBAS Core II showed good analytical performance and efficiency, particularly with its automatic dilution feature.
Supporting Evidence
- The COBAS Core II demonstrated intra-assay imprecision ranging from 1.8% to 4.9%.
- Inter-assay imprecision for the COBAS Core II ranged from 2.0% to 7.8%.
- Good correlation was found between the COBAS Core II and Abbott AxSYM for most assays.
Takeaway
The COBAS Core II is a machine that helps test for diseases quickly and accurately, making it easier for doctors to get results.
Methodology
The study evaluated the COBAS Core II analyser's performance over three months, comparing it with the Abbott AxSYM using over 600 patient samples.
Potential Biases
Potential bias due to the use of specific control sera and the limited sample diversity.
Limitations
The study was limited to a specific laboratory setting and may not generalize to all clinical environments.
Participant Demographics
Patients undergoing routine testing for thyroid and tumor markers.
Want to read the original?
Access the complete publication on the publisher's website